

Saving More Lives Through Immunotherapy

FAST FACTS

- \$336 MILLION INVESTED
- 3,000+ SCIENTISTS FUNDED
- NEARLY \$24 MILLION IN GRANTS AND EDUCATIONAL INITIATIVES IN FISCAL YEAR 2016
- 87% OF ANNUAL BUDGET DEVOTED TO PROGRAMS
- 80+ CLINICAL TRIALS CONDUCTED
- 1,100+ PATIENTS TREATED
- OUR FUNDING HAS HELPED MAKE THESE TREATMENTS POSSIBLE:
 - KEYTRUDA (MELANOMA, LUNG)
 - OPDIVO (MELANOMA, LUNG, KIDNEY)
 - YERVOY (MELANOMA)
 - BLINCYTO (LEUKEMIA)
 - PROVENGE (PROSTATE)
 - GARDASIL (CERVICAL)
 - HERCEPTIN (BREAST)
 - BCG (BLADDER)
 - INTERFERON ALPHA (LEUKEMIA, MELANOMA, LYMPHOMA)
 - AND MANY MORE
- CANCER IMMUNOTHERAPY VOTED "BREAKTHROUGH OF THE YEAR" IN 2013 (SCIENCE)

Pioneering Focus

Since 1953, Cancer Research Institute (CRI) has focused on a singular mission:

Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer.

Thanks to more than six decades of CRI-funded research, immunotherapy—which uses your body's own immune system to recognize and attack tumors—is turning the untreatable to the treatable, curing some cancer patients who had no other therapeutic options. CRI is leading the efforts to accelerate research and bring these new immunotherapies to patients faster.

Innovative Strategy

All our programs are strategically designed to address specific unmet needs and obstacles in cancer immunotherapy research and development, from supporting early discovery research, to conceiving and funding clinical trials, to providing feedback on regulatory rules. CRI funds top researchers from around the world, including postdoctoral fellows and more senior scientists and clinicians.

Impacting All Cancers

CRI scientists are working on therapies across a broad range of cancers, including:

- | | | |
|-----------------|--------------------|---------------------|
| • bladder | • kidney | • ovarian |
| • bone | • leukemia | • pancreatic |
| • brain | • liver | • pediatric cancers |
| • breast | • lung | • prostate |
| • cervical | • lymphoma | • sarcoma |
| • colorectal | • melanoma | • skin |
| • esophageal | • mesothelioma | • stomach |
| • head and neck | • multiple myeloma | |

Renowned Leadership

Our Scientific Advisory Council includes 3 Nobel Prize winners and 26 members of the National Academy of Sciences, and oversees all of CRI's programs. Our clinical trials are led by an international network of more than 90 top clinicians and scientists from over 40 of the world's leading medical research centers.

